Search - tctmd.com

Displaying 1 - 20 of 202

Sort: Relevancy | Date

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Daily News

Andexanet Alfa Pulled From US Market

Todd Neale

December 22, 2025

News Daily News

Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension

Todd Neale

October 07, 2025

News Conference News ESC 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

Todd Neale

August 31, 2025

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

Baxdrostat Shows Promise in Uncontrolled or Resistant Hypertension

L.A. McKeown

July 14, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

CV Screening, Care at UK Football Club Made Inroads Against HF

Caitlin E. Cox

March 07, 2025

News Daily News

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

Michael O'Riordan

March 03, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Shelley Wood

November 14, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

L.A. McKeown

February 23, 2024

Advertisement

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Andexanet Alfa Pulled From US Market

Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

What’s Going to Be Hot at ESC Congress 2025?

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

Baxdrostat Shows Promise in Uncontrolled or Resistant Hypertension

What’s Going to Be Hot at ACC 2025?

CV Screening, Care at UK Football Club Made Inroads Against HF

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Need a Statin for Primary Prevention? There’s an App for That

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content